- Home
- GNSS vs BCAB Comparison
GNSS vs BCAB Comparison
Compare GNSS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- BCAB
- Stock Information
- Founded
- GNSS 1992
- BCAB 2007
- Country
- GNSS United States
- BCAB United States
- Employees
- GNSS N/A
- BCAB N/A
- Industry
- GNSS Consumer Electronics/Appliances
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- GNSS Consumer Staples
- BCAB Health Care
- Exchange
- GNSS Nasdaq
- BCAB Nasdaq
- Market Cap
- GNSS 98.9M
- BCAB 22.3M
- IPO Year
- GNSS N/A
- BCAB 2020
- Fundamental
- Price
- GNSS $1.55
- BCAB $0.41
- Analyst Decision
- GNSS Strong Buy
- BCAB Buy
- Analyst Count
- GNSS 3
- BCAB 2
- Target Price
- GNSS $5.33
- BCAB $1.00
- AVG Volume (30 Days)
- GNSS 84.6K
- BCAB 561.7K
- Earning Date
- GNSS 08-05-2025
- BCAB 08-07-2025
- Dividend Yield
- GNSS N/A
- BCAB N/A
- EPS Growth
- GNSS N/A
- BCAB N/A
- EPS
- GNSS N/A
- BCAB N/A
- Revenue
- GNSS $27,780,000.00
- BCAB $11,000,000.00
- Revenue This Year
- GNSS $91.14
- BCAB N/A
- Revenue Next Year
- GNSS $75.44
- BCAB N/A
- P/E Ratio
- GNSS N/A
- BCAB N/A
- Revenue Growth
- GNSS N/A
- BCAB N/A
- 52 Week Low
- GNSS $1.46
- BCAB $0.24
- 52 Week High
- GNSS $4.04
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- GNSS 39.80
- BCAB 44.32
- Support Level
- GNSS $1.46
- BCAB $0.38
- Resistance Level
- GNSS $1.57
- BCAB $0.46
- Average True Range (ATR)
- GNSS 0.10
- BCAB 0.06
- MACD
- GNSS 0.00
- BCAB -0.01
- Stochastic Oscillator
- GNSS 23.08
- BCAB 9.36
About GNSS Genasys Inc.
Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.